Zydelig Approval History
FDA Approved: Yes (First approved July 23, 2014)
Brand name: Zydelig
Generic name: idelalisib
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
Zydelig (idelalisib) is a phosphoinositide 3-kinase (PI3K) delta inhibitor for the treatment of chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma.
Development History and FDA Approval Process for Zydelig
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.